Moreover, the combination of necroptosis activation and immune checkpoints inhibitors (ICIs) targeting the PD-1/PD-L1 pathway has been shown to improve treatment efficacy and survival in mouse models of melanoma and colorectal cancer compared to monotherapy [54]. The gene discussed is CD274; the disease is melanoma.